The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Rosa Ayala(Hospital Universitario 12 De Octubre), Olga Salamero(Vall d'Hebron Institut de Recerca), Esperanza Lavilla, Mar Tormo, Eva Barragán(Hospital Universitari i Politècnic La Fe), David Martínez‐Cuadrón(Instituto de Salud Carlos III), Felipe Prósper(Institute of Human Genetics), Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), José Falantes(Hospital Universitario Virgen del Rocío), Jorge Labrador(Hospital Universitario de Burgos), Inmaculada Rapado(Wellcome Sanger Institute), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Cristina Gil(Hospital General Universitario de Alicante Doctor Balmis), Jesús Lorenzo Algarra(Hospital General Universitario de Albacete), Josefina Serrano(Instituto Maimónides de Investigación Biomédica de Córdoba), Pilar Herrera(Hospital Universitario Ramón y Cajal), Fernando Ramos(Hospital de León), Bruno Paiva(Navarre Institute of Health Research), Esther Onecha(Hospital Universitario 12 De Octubre), José Luis López Lorenzo(Hospital Universitario Fundación Jiménez Díaz), Juan Bergua(Hospital San Pedro de Alcántara), María‐Belén Vídriales(Complejo Hospitalario de Salamanca), Gonzalo Carreño‐Tarragona, Susana Vives, Pilar Martı́nez(Research Institute Hospital 12 de Octubre), Pau Montesinos(Instituto de Salud Carlos III), María Belén Tarrafeta Sayas(Hospital Universitario Doctor Peset)
Cited by 12
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
|Cell|2020|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k